A dose‐dense short‐term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high‐risk Burkitt lymphoma or high‐grade B‐cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial

Abstract The majority of lymphomas in the setting of acquired, iatrogenic, or congenital immunodeficiencies are B-cell lymphoproliferations. We describe a rare T-cell lymphoma in a fulminantly ill patient infected with human immunodeficiency virus type 1 (HIV-1). The T-cell nature of the process was defined genotypically (monoclonal T-cell receptor beta- chain [CT beta] rearrangement) and phenotypically (CD45RO+, CD4+, CD5+, CD25+, CD8-, CD3- and negative for a variety of B-cell and monocyte markers). The CD4+, CD25+ (interleukin-2 receptor [IL-2R]) phenotype with production of IL-2 and IL-2R RNA is analogous to human T- lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia/lymphoma (ATLL); however, no HTLV-1 could be detected. Southern blot analysis did demonstrate monoclonally integrated HIV-1 within the tumor genome. Furthermore, the tumor cells were producing HIV p24 antigen as shown by immunohistochemistry. This is the first case of acquired immunodeficiency syndrome (AIDS)-associated non- Hodgkin's lymphoma in which HIV-1 infection may have played a central role in the lymphocyte transformation process.

Download Full-text

Diffuse Large B-cell Lymphoma Presenting as Acute Appendicitis in Patients With Acquired Immunodeficiency Syndrome

Infectious Diseases in Clinical Practice ◽

10.1097/ipc.0b013e318064634e ◽

2007 ◽

Vol 15 (6) ◽

pp. 411-414 ◽

Cited By ~ 3

Author(s):

Mahlet Tadele ◽

Stanley Yancovitz

Keyword(s):

Acute Appendicitis ◽

B Cell ◽

Acquired Immunodeficiency Syndrome ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Acquired Immunodeficiency ◽

Immunodeficiency Syndrome ◽

Large B Cell

Download Full-text

Acquired immunodeficiency syndrome-associated T-cell lymphoma: evidence for human immunodeficiency virus type 1-associated T-cell transformation

Blood ◽

10.1182/blood.v79.7.1768.bloodjournal7971768 ◽

1992 ◽

Vol 79 (7) ◽

pp. 1768-1774 ◽

Cited By ~ 1

Author(s):

BG Herndier ◽

BT Shiramizu ◽

NE Jewett ◽

KD Aldape ◽

GR Reyes ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

T Cell ◽

B Cell ◽

Virus Type ◽

Cell Lymphoma ◽

Immunodeficiency Virus ◽

Acquired Immunodeficiency ◽

Immunodeficiency Syndrome ◽

Hiv 1

The majority of lymphomas in the setting of acquired, iatrogenic, or congenital immunodeficiencies are B-cell lymphoproliferations. We describe a rare T-cell lymphoma in a fulminantly ill patient infected with human immunodeficiency virus type 1 (HIV-1). The T-cell nature of the process was defined genotypically (monoclonal T-cell receptor beta- chain [CT beta] rearrangement) and phenotypically (CD45RO+, CD4+, CD5+, CD25+, CD8-, CD3- and negative for a variety of B-cell and monocyte markers). The CD4+, CD25+ (interleukin-2 receptor [IL-2R]) phenotype with production of IL-2 and IL-2R RNA is analogous to human T- lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia/lymphoma (ATLL); however, no HTLV-1 could be detected. Southern blot analysis did demonstrate monoclonally integrated HIV-1 within the tumor genome. Furthermore, the tumor cells were producing HIV p24 antigen as shown by immunohistochemistry. This is the first case of acquired immunodeficiency syndrome (AIDS)-associated non- Hodgkin's lymphoma in which HIV-1 infection may have played a central role in the lymphocyte transformation process.

Download Full-text

Specific translocations characterize Burkitt's-like lymphoma of homosexual men with the acquired immunodeficiency syndrome

Blood ◽

10.1182/blood.v61.6.1265.1265 ◽

1983 ◽

Vol 61 (6) ◽

pp. 1265-1268 ◽

Cited By ~ 84

Author(s):

RS Chaganti ◽

SC Jhanwar ◽

B Koziner ◽

Z Arlin ◽

R Mertelsmann ◽

...

Keyword(s):

Acquired Immunodeficiency Syndrome ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

The Other ◽

Homosexual Men ◽

Immunoglobulin Genes ◽

Chromosome Translocations ◽

Cytogenetic Studies ◽

Acquired Immunodeficiency ◽

Immunodeficiency Syndrome

Abstract A Burkitt's-like B-cell lymphoma (BLL) has recently been shown to be associated with the acquired immunodeficiency syndrome (AIDS), which affects homosexual men. We report cytogenetic studies of two BLL tumors in homosexual men. Both tumors had chromosome translocations characteristic of Burkitt's lymphoma (BL), one the t(8;14) and the other the t(8;22). The pathway of lymphomagenesis in this disorder is discussed in the light of recent data on chromosome change and localization of immunoglobulin genes and oncogenes.

Download Full-text

Primary parotid B-cell lymphoma successfully treated with chemotherapy plus highly active antiretroviral therapy with prolonged survival and immune reconstitution in an acquired immunodeficiency syndrome patient: Case report and review of the literature

Clinical Cancer Investigation Journal ◽

10.4103/2278-0513.138062 ◽

2014 ◽

Vol 3 (5) ◽

pp. 401 ◽

Cited By ~ 1

Author(s):

Marcelo Corti ◽

Alicia Bistmans ◽

Marina Narbaitz

Keyword(s):

Highly Active Antiretroviral Therapy ◽

Immune Reconstitution ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Syndrome Patient ◽

Review Of The Literature ◽

Patient Case ◽

Highly Active ◽

Acquired Immunodeficiency ◽

Immunodeficiency Syndrome

Download Full-text

3′-Azido 3′-Deoxythymidine + Methotrexate as a Novel Antineoplastic Combination in the Treatment of Human Immunodeficiency Virus-Related Non-Hodgkin's Lymphomas

Blood ◽

10.1182/blood.v89.2.419 ◽

1997 ◽

Vol 89 (2) ◽

pp. 419-425 ◽

Cited By ~ 16

Author(s):

Patrizia Tosi ◽

Filippo Gherlinzoni ◽

Patrizio Mazza ◽

Giuseppe Visani ◽

Olga Coronado ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Confidence Interval ◽

De Novo ◽

Treatment Plan ◽

B Cell Lymphoma ◽

Immunodeficiency Virus ◽

Acquired Immunodeficiency ◽

Hodgkin's Lymphomas ◽

Immunodeficiency Syndrome ◽

Thymidylate Synthesis

Abstract We have previously reported that 3′-azido 3′-deoxythymidine (AZT) can possess a significant antineoplastic activity when combined with drugs that disrupt de novo thymidylate synthesis, such as 5-fluorouracil and methotrexate (MTX). The aim of the present study was to evaluate the efficacy and the tolerance of the combination AZT + MTX in human immunodeficiency virus (HIV)-related non-Hodgkin's lymphoma (NHL). Twenty-nine patients (22 men and 7 women), either newly diagnosed or pretreated, have been enrolled in the trial; the median age was 34 years, 45% had acquired immunodeficiency syndrome before lymphoma and 19 patients had less than 100 CD4 lymphocytes/μL. Histologic diagnoses were mainly Burkitt (27%) and diffuse large B-cell lymphoma (45%); extranodal involvement was present in 20 patients. The treatment plan included three weekly courses of MTX at 1 g/m2 (days 1, 8, and 15) plus oral AZT at 2 g/m2 (days 1, 2, and 3), 4 g/m2 (days 8, 9, and 10), and 6 g/m2 (days 15, 16, and 17), plus leucovorin rescue. From the eleventh patient on, in case of complete or partial remission, the treatment was continued with three additional courses, using AZT at the maximum dose. In 26 evaluable patients, the total (complete + partial) response rate was 77% (95% confidence interval, 58% to 89%), with complete remission (CR) in 46% of the patients (95% confidence interval, 29% to 65%). The median CR duration was 12.8 months. Grade III-IV neutropenia and anemia were observed in 52% and 31% of the courses, respectively. There was one therapy-related death due to bacteremia followed by septic shock; the only other recorded infection was a herpes vaginalis. In conclusion, we suggest that AZT + MTX is an effective and well-tolerated regimen in HIV-related NHL.

Download Full-text